Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT-Reference-Cited by-同舟云学术

Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT

Published:2020-04 Issue: Volume:50 Page:64-70
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Steger Guenther G.,Egle Daniel,Bartsch Rupert,Pfeiler Georg,Petru Edgar,Greil Richard,Helfgott Ruth,Marth Christian,Öhler Leopold,Hubalek Michael,Lang Alois,Tinchon Christoph,Haslbauer Ferdinand,Redl Andreas,Hock Karin,Hennebelle Mathias,Mraz Bernhard,Gnant Michael

Funder

Novartis Austria GmbH

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference16 articles.

1. Understanding breast cancer - the long and winding road;Lukong;BBA Clin,2017

2. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018;Ferlay;Eur J Canc,2018

3. Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition;Gnant;Expert Rev Anticancer Ther,2012

4. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2);Cardoso;Breast,2014

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognosis of patients treated with everolimus for advanced ER‐positive, HER2‐negative breast cancer is driven by molecular features;The Journal of Pathology: Clinical Research;2024-04-02

2. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor‐positive, HER‐2‐negative advanced breast cancer: Results from the open‐label, multicentre, non‐interventional BRAWO study;International Journal of Cancer;2024-03-06

3. Efficacy of everolimus‐based therapy in advanced triple‐positive breast cancer: Experience from three cancer centers in China;Thoracic Cancer;2023-11-07

4. Safety and efficacy of everolimus plus exemestane in postmenopausal women with treatment-refractory hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis from EVEREXES Taiwan subset;Journal of Cancer Research and Practice;2023

5. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE);ESMO Open;2022-12